Drug details

Varubi (rolapitant tablets)

type of Antiemetic Agents, NK1 Receptor Antagonists

Varubi (rolapitant) Tablets is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic (antinausea) agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic (nausea-causing) cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

This drug may have the following side effects:

• dizziness
• anemia
• abdominal pain
• indigestion
• hiccups
• urinary tract infection
• decreased appetite
• low white blood cell count (neutropenia)
• swelling and sores inside the mouth (stomatitis)

The following drugs are related to Varubi, either as a replacement or used together:

• Aloxi (palonosetron hydrochloride)
• Aloxi Capsules (palonosetron hcl capsules)
• Anzemet Injection (dolasetron mesylate injection)
• Anzemet Tablets (dolasetron)
• Aponvie (aprepitant injectable emulsion)
• Emend Capsules (aprepitant capsules)
• Cesamet (nabilone capsules)
• Marinol (dronabinol capsules)
• Emend Injection (fosaprepitant dimeglumine injection)
• Kytril (granisetron)
• Kytril Injection (granisetron hydrochloride)
• Zofran Injection (ondansetron hydrochloride injection)
• Zofran (ondansetron hydrochloride tablets and solution)